PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
799.80%
Cash & equivalents growing 799.80% while AVXL's declined -3.26%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
799.80%
Below half of AVXL's -3.26%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
700.88%
Below half of AVXL's -1.28%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.67%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.93%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Below half of AVXL's -1.28%. Michael Burry sees a potential red flag for stagnation or capital shortage.
1.26%
Less than half of AVXL's 16.70%. David Dodd sees a more disciplined AP approach or lower volume.
-42.54%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
5.04%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-1.15%
Less than half of AVXL's 14.00%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Less than half of AVXL's 10.39%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.99%
Less than half of AVXL's 14.00%. David Dodd sees far fewer liability expansions relative to competitor.
-92.57%
Less than half of AVXL's 2.77%. David Dodd sees fewer share issuances vs. competitor.
-2.16%
Below half AVXL's -5.17%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1581.26%
Below half AVXL's -4.50%. Michael Burry sees potential underperformance in building shareholder capital.
569.03%
Below half AVXL's -1.28%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-1028.99%
Less than half of AVXL's 3.26%. David Dodd sees better deleveraging or stronger cash buildup than competitor.